Background: Literature shows various benefits of Transoral robotic surgery (TORS) for the management of oropharyngeal tumors. The aim of this prospective study was to evaluate the recurrence at one year follow-up of patients having early tumors of oropharynx undergoing Transoral Robotic Surgery. Material & methods: This prospective study was conducted in patients of T1 & T2 tumours of the oropharynx who were treated by Transoral robotic Surgery between the period August 2016 to October 2018 at the Department of Otolaryngology and Head and Neck surgery, PGIMER, Chandigarh. During this period 42 patients were operated by TORS. All the patients were asked to follow up once in 2 months up to a period of 1 year and disease free survival and recurrence rate was noticed. Results: The mean age of patients enrolled in the study was 53.17 ± 11.491years, range being 28 - 70 years there were 38 males (90.5%) and 4 females (9.5%) in the study with a male to ratio of 9.5:1. A total of 5 patients had Recurrence after 1 year of follow up. Recurrence was in one patient of Soft palate and 4 patients of carcinoma Tonsil. No recurrence was seen in patients with Base of tongue malignancy. Recurrence was seen in 2 patients in stage I and 3 patients in stage II. The difference was statistically not significant (p=0.365).Recurrence was found in three patients in Salvage group and in 2 patients where surgery was done as Upfront (primary modality). There was not statistically significant difference (p=0.072). Two patients had recurrence even with surgical margins being free and three patients had recurrence in which margins were positive on histopathology. Statistically this difference was not significant (p=0.072). 3 patients had recurrence in which post operative resection margins were free and two patients had recurrence in which deep resection margins were involved(p=1.00) 12 patients out of 16 patients completed one year follow up who received adjuvant radiotherapy and there was no recurrence of tumor in these patients. No evidence of recurrence was seen in two patients who were HPV positive. Conclusion: TORS has also shown promise in the salvage setting to provide recurrence free survival.